Basma Adeem Medical (9626) Fundamentals 2026 — P/E 10.0x, Revenue Analysis | SniperIQ
Basma Adeem Medical (9626) is a SA-listed Healthcare company in Medical - Care Facilities with a market capitalization of SAR 121M, trading at SAR 6.06 on the SAU. This SniperIQ fundamentals page covers Basma Adeem Medical's valuation (P/E 10.0x, P/B 2.3x), profitability (net margin 16.1%), revenue (SAR 45M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Basma Adeem Medical's market cap?
Basma Adeem Medical (9626) has a market capitalization of approximately SAR 121M, trading at SAR 6.06 on the SAU. Market cap moves with the live share price.
What is Basma Adeem Medical's P/E ratio?
Basma Adeem Medical's trailing twelve-month P/E ratio is 10.0x, with a price-to-book (P/B) of 2.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Basma Adeem Medical?
Basma Adeem Medical runs a net profit margin of 16.1%, a gross margin of 29.3%, and an operating margin of 21.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Basma Adeem Medical generate?
Basma Adeem Medical reported revenue of SAR 45M for fiscal year 2025, with net income of SAR 7M and earnings per share (EPS) of 0.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Basma Adeem Medical pay a dividend?
Basma Adeem Medical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Basma Adeem Medical financially healthy?
Basma Adeem Medical carries a debt-to-equity ratio of 0.31x and a current ratio of 6.55x, with a market beta of 0.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Basma Adeem Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Basma Adeem Medical (9626) the key facts are: market cap SAR 121M, P/E 10.0x, revenue SAR 45M, 52-week range 4.75-6.46. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Basma Adeem Medical's full fundamentals live
Get Basma Adeem Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.